Medical Device

During Q4, biopharmas brought in an aggregate $30bn in financing and device company fundraising totaled $9.7bn; while in vitro diagnostic firms and research tools players raised $1.5bn.

With capital being recycled, tariffs settling and interest rates softening, 2026 could provide more investment and growth opportunities in pharma and medtech, with AI giving a tailwind, say Taylor Wessing’s Ross McNaughton and Sarah Cole.

If medtech regulation is to work for patients, industry and society, Europe must move from political positioning to evidence-driven policymaking. It is time to avoid repeating the self-destructive cycle.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

AI promises to be the much-needed solution to the now overly complex field of EU medtech regulatory affairs. Will every stakeholder start using solutions such as Raiana?

The medtech industry has been disrupted by tariffs and China’s volume-based procurement policies. While India is expected to emerge as a key long-term growth market, near-term upside may come from a potential rebound in EU attractiveness following the MDR reform proposals in December 2025.

EIT Health has helped 3,000 start-ups and SMEs scale across Europe and supported over 120 innovations to launch. Inspired by the US MIT, the EIT Health program is on a mission to raise awareness of its value to healthtech innovators as it embarks on new methods of funding its own activities.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

The European Commission’s proposal does not envisage a single centralized medtech agency, but instead sets out a targeted redistribution of tasks that could strengthen the existing framework. Professor Tom Melvin told Medtech Insight how.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

FDA updates pair of guidance documents relaxing its posture on how it regulates general wellness devices and clinical support software. Industry mostly welcomes changes, agreeing with agency’s view that lighter regulation will help spur innovation.

It’s time for In Vivo's 18th annual Deals of the Year contest. We've chosen 15 nominees across three categories – Top M&A, Top Alliance, and Top Financing – and now it’s your turn to pick the winners.